Go Deep
Decoy Therapeutics Inc.
Decoy Therapeutics Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 25,958 | 0.1 | 0.68 | 0.00 | 116.50 |
| Oct 2026 | 25,980 | 0.1 | 0.65 | 0.00 | 110.82 |
| Oct 2026 | 23,876 | 0.1 | 0.65 | 0.00 | 110.94 |
| Oct 2026 | 23,887 | 0.1 | 0.63 | 0.00 | 107.62 |
| Oct 2026 | 23,907 | 0.1 | 0.59 | 0.00 | 101.20 |
| Oct 2026 | 23,922 | 0.1 | 0.57 | 0.00 | 97.22 |
Decoy Therapeutics Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -2,373,800.0 | -2,224,628.0 | -8,977,655.0 | -873,467.0 |
| EPS | -4.5 | -4.2 | — | -21.7 |
Decoy Therapeutics Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Net Profit | -12,518,480.0 | -5,575,777.0 | -12,542,693.0 | -31,607,956.0 | — |
| EPS | -129.1 | -1,043.1 | -5,533.2 | -21,427.2 | — |
Decoy Therapeutics Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 11,056,707.0 | 3,022,974.0 | 6,586,523.0 | 14,650,799.0 | — |
| Total Liabilities | 5,167,738.0 | 1,511,279.0 | 1,299,241.0 | 4,266,191.0 | — |
| Total Equity | 5,888,969.0 | 1,511,695.0 | 5,287,282.0 | 10,384,608.0 | — |
Owes vs Owns
Decoy Therapeutics Inc. owed $0.52 for every $1 it owned in Jun 2026, up from $0.29 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.52× | 0.47× | 0.50× | 0.20× | 0.29× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Decoy Therapeutics Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 96.9%Other assets 2.8%
How it's funded — Dec 2025
Payables 8.5%Other liabilities 38.2%Shareholders' equity 53.3%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 10.7 | 2.4 | 5.9 | 12.1 |
| Receivables | 0.0 | 0.0 | 0.0 | 1.6 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 0.0 | 0.0 | 0.0 | 0.0 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 0.3 | 0.6 | 0.7 | 0.9 |
| Liabilities & equity | ||||
| Short-term debt | 0.0 | 0.2 | 0.3 | 0.0 |
| Long-term debt | 0.0 | 0.0 | 0.0 | 0.0 |
| Payables | 0.9 | 0.9 | 0.6 | 2.9 |
| Other liabilities | 4.2 | 0.4 | 0.4 | 1.4 |
| Shareholders' equity | 5.9 | 1.5 | 5.3 | 10.4 |
| Net tangible assets | 5.9 | 1.5 | 5.3 | 10.4 |
Decoy Therapeutics Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -4,827,188.0 | -4,525,337.0 | -12,846,137.0 | -17,595,321.0 | — |
| Investing Activities | 764,735.0 | 0.0 | 0.0 | -1,500,000.0 | — |
| Financing Activities | 12,337,862.0 | 1,059,955.0 | 6,639,612.0 | 1,987,376.0 | — |